

Big Pharma Eyes Claris' Injectables Biz for ₹3kcr

Cipla, Lupin and US' Amneal among cos in race

Arijit.Barman@timesgroup.com

Mumbai: Several Indian pharma giants are competing with global peers to acquire the generic sterile injectables business of Ahmedabad-based Claris Lifesciences, signalling the continuing appeal of quality Indian pharma assets. The interest from strategic players also coincides with a global scramble for companies making injectables — drugs that are delivered through vials, syringes and bags, as well as pumps — that has driven many recent transactions.


US Market Key Growth Driver >> 18

Show Me The Money

Claris Injectables has 3 plants in Gujarat

Customer base: Govt, private hospitals, aid agencies

Products used for critical illness therapeutic segment



₹2.5K-3K cr
Valuation expectation

₹1,320 cr
Market cap of parent CLL

KEY MARKET: US

Company